ToxSci Advance Access originally published online on May 17, 2006
Toxicological Sciences 2006 92(2):578-586; doi:10.1093/toxsci/kfl019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agonists of the Peroxisome ProliferatorActivated Receptor Alpha Induce a Fiber-TypeSelective Transcriptional Response in Rat Skeletal Muscle
Rosetta Inpharmatics LLC, Merck & Co, Inc, Seattle, Washington 98109
Received January 20, 2006; accepted April 11, 2006
In rodents, treatment with peroxisome proliferatoractivated receptor alpha (PPAR
) agonists results in peroxisome proliferation, hepatocellular hypertrophy, and hepatomegaly. Drugs in the fibrate class of PPAR
agonists have also been reported to produce rare skeletal muscle toxicity. Although target-driven hepatic effects of PPAR
treatment have been extensively studied, a characterization of the transcriptional effects of this nuclear receptor/transcription factor on skeletal muscle responses has not been reported. In this study we investigated the effects of PPAR
agonists on skeletal muscle gene transcription in rats. Further, since statins have been reported to preferentially effect type II muscle fibers, we compared PPAR
signaling effects between type I and type II muscles. By comparing the transcriptional responses of agonists that signal through different nuclear receptors and using a selection/deselection analytical strategy based on ANOVA, we identified a PPAR
activation signature that is evident in type I (soleus), but not type II (quadriceps femoris), skeletal muscle fibers. The fiber-typeselective nature of this response is consistent with increased fatty acid uptake and ß-oxidation, which represent the major clinical benefits of the hypolipidemic compounds used in this study, but does not reveal any obvious off-target pathways that may drive adverse effects.
Key Words: peroxisome proliferatoractivated receptor alpha (PPAR
); microarray; fenofibrate; Wy-14,643; liver.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Faiola, J. G. Falls, R. A. Peterson, N. R. Bordelon, T. A. Brodie, C. A. Cummings, E. H. Romach, and R. T. Miller PPAR alpha, more than PPAR delta, Mediates the Hepatic and Skeletal Muscle Alterations Induced by the PPAR Agonist GW0742 Toxicol. Sci., October 1, 2008; 105(2): 384 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Pritt, D. G. Hall, J. Recknor, K. M. Credille, D. D. Brown, N. P. Yumibe, A. E. Schultze, and D. E. Watson Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers Toxicol. Sci., June 1, 2008; 103(2): 382 - 396. [Abstract] [Full Text] [PDF] |
||||
